Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model

Hung,Ming-Szu; Xu,Zhidong; Chen,Yu; Smith,Emmanuel; Mao,Jian-Hua; Hsieh,David; Lin,Yu-Ching; Yang,Cheng-Ta; Jablons,David  M.; You,Liang

doi:10.3892/ijo.2013.2087

Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model

Authors:
- Ming-Szu Hung
- Zhidong Xu
- Yu Chen
- Emmanuel Smith
- Jian-Hua Mao
- David Hsieh
- Yu-Ching Lin
- Cheng-Ta Yang
- David M. Jablons
- Liang You
View Affiliations

Affiliations: Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA, Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, FL, USA, Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA, USA, Division of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi branch, Taoyuan, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Taoyuan branch, Taoyuan, Taiwan, R.O.C.
Published online on: September 4, 2013 https://doi.org/10.3892/ijo.2013.2087
Pages: 1517-1522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Casein kinase II (CK2) inhibitors suppress cancer cell growth. In this study, we examined the inhibitory effects of a novel CK2 inhibitor, hematein, on tumor growth in a murine xenograft model. We found that in lung cancer cells, hematein inhibited cancer cell growth, Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway and increased apoptosis. In a murine xenograft model of lung cancer, hematein inhibited tumor growth without significant toxicity to the mice tested. Molecular docking showed that hematein binds to CK2α in durable binding sites. Collectively, our results suggest that hematein is an allosteric inhibitor of protein kinase CK2 and has antitumor activity to lung cancer.

View Figures

View References

1.	Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17:349–368. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Pinna LA: The raison d’etre of constitutively active protein kinases: the lesson of CK2. Acc Chem Res. 36:378–384. 2003.
3.	Tawfic S, Yu S, Wang H, Faust R, Davis A and Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol. 16:573–582. 2001.PubMed/NCBI
4.	Seldin DC and Leder P: Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science. 267:894–897. 1995. View Article : Google Scholar : PubMed/NCBI
5.	Landesman-Bollag E, Song DH, Romieu-Mourez R, et al: Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem. 227:153–165. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Kim JS, Eom JI, Cheong JW, et al: Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res. 13:1019–1028. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL and Cochet C: Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer. 43:928–934. 2007. View Article : Google Scholar : PubMed/NCBI
8.	O-charoenrat P, Rusch V, Talbot SG, et al: Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res. 10:5792–5803. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Gapany M, Faust RA, Tawfic S, Davis A, Adams GL and Ahmed K: Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med. 1:659–666. 1995.PubMed/NCBI
10.	Stalter G, Siemer S, Becht E, Ziegler M, Remberger K and Issinger OG: Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun. 202:141–147. 1994. View Article : Google Scholar : PubMed/NCBI
11.	Ruzzene M, Penzo D and Pinna LA: Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J. 364:41–47. 2002.
12.	Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z and Pinna LA: 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun. 321:1040–1044. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Sarno S, De Moliner E, Ruzzene M, et al: Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl] acetic acid (IQA). Biochem J. 374:639–646. 2003.PubMed/NCBI
14.	Siddiqui-Jain A, Drygin D, Streiner N, et al: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70:10288–10298. 2010. View Article : Google Scholar
15.	Hung MS, Xu Z, Lin YC, et al: Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer. 9:1352009. View Article : Google Scholar : PubMed/NCBI
16.	Oh SR, Kim DS, Lee IS, Jung KY, Lee JJ and Lee HK: Anti-complementary activity of constituents from the heartwood of Caesalpinia sappan. Planta Med. 64:456–458. 1998. View Article : Google Scholar : PubMed/NCBI
17.	Bettinger C and Zimmermann HW: New investigations on hematoxylin, hematein, and hematein-aluminium complexes. II. Hematein-aluminium complexes and hemalum staining. Histochemistry. 96:215–228. 1991. View Article : Google Scholar : PubMed/NCBI
18.	Lorber DM and Shoichet BK: Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem. 5:739–749. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Raaf J, Brunstein E, Issinger OG and Niefind K: The CK2 alpha/ CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol. 15:111–117. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Meng EC, Shoichet BK and Kuntz ID: Automated docking with grid-based energy evaluation. J Computat Chem. 13:505–524. 1992. View Article : Google Scholar
21.	Raaf J, Issinger OG and Niefind K: Insights from soft X-rays: the chlorine and sulfur sub-structures of a CK2alpha/DRB complex. Mol Cell Biochem. 316:15–23. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Di Maira G, Salvi M, Arrigoni G, et al: Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 12:668–677. 2005.PubMed/NCBI
23.	Duncan JS and Litchfield DW: Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 1784:33–47. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG and Stenvang J: Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett. 256:229–237. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Tapia JC, Torres VA, Rodriguez DA, Leyton L and Quest AF: Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA. 103:15079–15084. 2006. View Article : Google Scholar
26.	Ponce DP, Yefi R, Cabello P, et al: CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem. 356:127–132. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Moucadel V, Prudent R, Sautel CF, et al: Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget. 2:997–1010. 2011.PubMed/NCBI